Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer

Fig. 5

Treatment related adverse events. UX (Utidelone plus Capecitabine); Eri (Eribulin). A Distribution of adverse reactions at any level in the UX group. B Distribution of adverse reactions at any level in the Eri group. C Classification of toxic and side effects in the UX group. D Classification of toxic and side effects in the Eri group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us